Qualigen Therapeutics Inc
Change company Symbol lookup
Select an option...
QLGN Qualigen Therapeutics Inc
CO Global Cord Blood Corp
KRP Kimbell Royalty Partners LP
VIRX Viracta Therapeutics Inc
ONFO Onfolio Holdings Inc
DCPH Deciphera Pharmaceuticals Inc
MET MetLife Inc
MSM MSC Industrial Direct Co Inc
BAC Bank of America Corp

Health Care : Biotechnology | Small Cap Value
Company profile

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer. The Company's cancer therapeutics pipeline includes QN-302, QN-247 and RAS-F. QN-302 compound is a small molecule genomic quadruplex (G4) selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate to target various types of cancer. RAS-F is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins and preventing this binding to stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. Its pipeline also includes QN-165, a drug candidate for treating COVID-19 and other viral-based infectious diseases.

Closing Price
Day's Change
0.0161 (1.29%)
B/A Size
Day's High
Day's Low

10-day average volume:
Latest Earnings Beat Consensus (Q3 ending 09/2022)Next Earnings Announcement
Announced November 14, 2022
-$1.00Q3 Consensus
of 2 analysts
-$1.30Difference from
Q4 Earnings
will announce

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



QLGN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.